Truist assumed coverage of ArriVent Biopharma with a Buy rating with a price target of $45, up from $43. The firm views the company's firmo - firmonertinib - as well-positioned across the EGFR Ex20ins and PACC mutation NSCLC - non-small cell lung cancer - landscape, supported by an encouraging efficacy and tolerability profile that underpins its $1.1B peak revenue estimate for ArriVent, the analyst tells investors in a research note.
